IFFIm stands ready to support COVID-19 vaccines
IFFIm stands ready to support COVID-19 vaccines
9 April 2020
Credit: Gavi/2020/Isaac Griberg
Fast, flexible financing could be a game-changer in fighting the virus.
Fast, flexible financing could be a game-changer in fighting the virus
As COVID-19 cases mount around the world, scientists are pulling out all the stops to find a safe and viable vaccine. G20 leaders have pledged to “do whatever it takes” to combat the deadly virus. An analysis estimates it will take US$ 7 trillion to combat the coronavirus and rescue the economies devastated in its wake. This includes lower-income countries needing additional support to address the current crisis and, we hope, to purchase and roll out COVID-19 prevention measures and treatments.
Make no mistake: it will be an enormous challenge to raise the massive amounts of immediate funding needed during a worldwide economic crisis.
There are solutions to this funding gap. Countries could promise to pay for this life-saving vaccine by spreading out the costs over many years, and the private sector can invest to raise the total amount of the funding against those future payments – funding that can be put to use right now.
We already have a proven and trusted financing tool to make this possible: IFFIm, the International Finance Facility for Immunisation. Since its first Vaccine Bond issuance in 2006, IFFIm has enabled Gavi, the Vaccine Alliance to pay for pressing immunisation programmes, as well as for polio eradication, vaccine stockpiles and health system strengthening.
Now, subject to Gavi approval and additional donor pledges, IFFIm could be put to work to raise fast, flexible financing on a large scale to fund the development a COVID-19 vaccine as well as its rapid deployment to affected countries once available.
So far, ten countries have committed to pay out more than US$ 6.5 billion to IFFIm over 10 to 23 years. Against those pledges, IFFIm’s Vaccine Bonds have raised about $6.1 billion from private sector investors around the world and provided $2.6 billion of immediately available funding for Gavi. IFFIm then pays back those investors at a competitive rate of return.
IFFIm issued a bond in 2019 against a long-term commitment from the Norwegian Government to raise funding for the Coalition for Epidemic Preparedness and Innovation, or CEPI, which supports the creation of new vaccines against deadly infectious diseases. Backed by donors, CEPI has announced a new partnership to develop a vaccine for COVID-19.
Others are also using social bonds to meet he urgent needs of our current crisis. The African Development Bank (AfDB), for example, has already raised $3 billion in a 3-year bond to help alleviate the economic and social impact the COVID-19 pandemic will have on livelihoods and Africa’s economies.
With the IFFIm financing model, the world can provide funding not just when it’s available – which could be too late – but immediately. IFFIm has worked before to fund programmes that preserve and protect people’s health. It’s a proven solution that could help the world overcome an unprecedented challenge.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.